UPDATE: Ascendiant Capital Downgrades Solta Medical to Buy Following Poor Execution

In a report published Friday, Ascendiant Capital analyst Keay Nakae downgraded the rating on Solta Medical (NASDAQ: SLTM ) from Strong Buy to Buy, and lowered the price target from $3.50 to $2.25. In the report, Nakae noted, “We believe that Solta has now become a ‘show me' stock. While